Bovilis Huskvac is a vaccine used for immunisation against husk or lungworm infection in cattle. Bovilis Huskvac is highly effective and important for the development of immunity. Despite the fact that Bovilis Huskvac is still available, a high number of farmers have discontinued the use of the vaccine, and a sharp increase in husk cases throughout the country especially in adult cattle has been reported. Vaccination against husk is a vital component in a cattle worm control strategy. Bovilis Huskvac may only be prescribed by your veterinary surgeon from whom advice should be sought. Further information is available on request.
SUSPENSION FOR ORAL ADMINISTRATION IN CATTLE
Each single dose (25 ml) contains at least 1000 viable Dictyocaulus viviparus 3rd stage irradiated larvae.
For the active immunisation of cattle to reduce clinical signs and lesions of parasitic bronchitis attributable to Dictyocaulus viviparus (Lungworm).
Immunity develops by 2 weeks after the final vaccination. Lungworm immunity is maintained from season to season by the exposure to lungworm larvae, which in most cases occurs from the grazing of normal pastures.
Dosage and administration
Vaccinate healthy animals of 8 weeks of age and older.
Can be used during pregnancy.
Shake bottle well immediately before use and administer the full dose (25 ml) orally.
Basic vaccination scheme
Two doses at a dosage interval of approximately 4 weeks.
Lungworm immunity is maintained from season to season by the exposure to lungworm larvae, which in most cases occurs from the grazing of normal pastures after vaccination. A single dose of Bovilis Huskvac prior to each season’s turnout will boost immunity where such exposure has not occurred, e.g. extensive use of anthelmintics or if using reserved or clean pasture for a large part of the grazing season.
Contra-indications, warnings, etc.
Only healthy calves should be vaccinated.
Bovilis Huskvac must not be given to calves showing any signs of illness, particularly those exhibiting any signs of respiratory distress.
Transient episodes of coughing may occur approximately 7 days after either of the two Bovilis Huskvac administrations but these usually subside in a few days. After administration of an overdose no other symptoms than those described above were monitored.
Following vaccination, vaccinated stock should not be mixed with unvaccinated stock or allowed to graze on pastures recently used by unvaccinated stock until 2 weeks after the second dose of Bovilis Huskvac.
Note: For optimum benefit it is important that the calf is exposed to pasture carrying some infection after this time, as this low level exposure enhances the immunity induced by vaccination with Bovilis Huskvac.
No information is available on the safety and efficacy from the concurrent use of this vaccine with any other. It is therefore recommended that no other vaccines should be administered within 14 days before or after vaccination with Bovilis Huskvac.
Do not mix with any other medicinal product.
Owing to variations in residual activity of modern anthelmintics, the use of these preparations must be avoided from a period extending from 8 weeks before the first dose until 14 days after the second dose of Bovilis Huskvac. The same condition applies to sustained release anthelmintic boluses, which must be avoided completely until 14 days after the second dose of Bovilis Huskvac, after which time no interference with immunity to lungworm vaccination should occur.
Routine vaccination of housed or suckled young stock prior to exposure to field lungworm challenge will help protect the calves and help reduce the levels of pasture contamination with lungworm larvae. However, owing to the ability of lungworm larvae to survive on pasture, calfhood vaccination programmes to control lungworm infection can only be successful if all susceptible calves are vaccinated in the spring before exposure to natural field infection occurs at turnout or weaning.
A good immune response is reliant on the reaction of an immunogenic agent and a fully competent immune system. Immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration. Immuno-competence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.
Wash hands after use.
FOR ANIMAL TREATMENT ONLY. KEEP OUT OF REACH AND SIGHTOF CHILDREN.
Store at +2°C to +8°C. Do not freeze.
Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant in accordance with national requirements.
POM-V To be supplied only on veterinary prescription.
Carton containing 12 bottles with 25 ml larval suspension in 30 ml glass hydrolytic class type III bottles, closed with a metal screw cap with a PEP inlay.
Marketing Authorisation number
Vm 01708/4328 UK Authorised veterinary medicinal product.
Marketing Authorisation holder
Intervet UK Ltd,
Bucks. MK7 7AJ.
Licensed distributor in Northern Ireland
Intervet Ireland Ltd.
Magna Business Park